Empagliflozin Lowers Norepinephrine Turnover Despite Raising Hepatic Glucose Production
A mechanistic randomized trial found empagliflozin reduced total-body norepinephrine turnover at 1 day and 12 weeks even as hepatic glucose production rose, with the two changes inversely correlated. PICO summary and expert commentary.
